HeraMED Advances US Growth with Philips and Lee Health Scaling

Philips Partnership Transitions to Commercial Sales

HeraMED Limited (ASX:HMD) has advanced its US commercial ambitions by moving the Philips partnership beyond framework discussions into an active joint sales strategy targeting hospitals within Philips' extensive US network. The collaboration, formalised in late 2025, is now focused on refining deployment models to enable systematic rollout across Philips' health system relationships. The deepening engagement suggests both parties are negotiating a more substantive commercial framework to support scaled hospital adoption.

This progression marks a crucial shift from planning to execution, with HeraMED confident of leveraging Philips' established channels to accelerate its HeraCARE platform's penetration in the US maternity care market. The company anticipates providing more detailed updates on this commercial opportunity in the next quarter. This builds on earlier momentum from the initial commercial agreement signed in November 2025, as documented in the Philips commercial agreement announcement.

Lee Health Pilot Validates Platform with Plans for Expansion

Meanwhile, HeraMED’s pilot program with Lee Health, a major non-profit health system in Southwest Florida delivering approximately 8,000 babies annually, has demonstrated strong patient satisfaction and adherence across prenatal and postpartum cohorts. The initial phase has validated HeraCARE's clinical workflow within a real-world US health system setting, reinforcing the platform’s usability and patient engagement credentials.

Encouraged by these outcomes, both HeraMED and Lee Health are actively preparing for Phase 2, which aims to scale the program to around 2,000 pregnancies. This next phase will shift focus toward clinical outcomes, operational efficiency, and scalability across the broader Lee Health network. The pilot’s expansion is a key step in building the clinical evidence base and recurring revenue streams essential for HeraMED’s commercialisation strategy, complementing its Philips partnership and direct sales efforts. The pilot’s origins and initial scope were outlined in the Lee Health pilot launch release.

Strengthening US Commercial Leadership and Financial Position

To support its US commercial push, HeraMED appointed Dr Adam Myers as Chairman of its Commercial Scientific Advisory Board. Dr Myers brings extensive US health system, payer, and clinical leadership experience, having held senior roles at Telus Health, Cleveland Clinic, and Blue Cross Blue Shield Association. His blend of frontline obstetric practice and executive leadership is expected to enhance HeraMED’s commercialisation and reimbursement strategies as the company scales HeraCARE across major health systems.

Financially, HeraMED closed the March quarter with a solid cash balance of A$3.145 million, bolstered by a $3.2 million capital raise completed in early 2026. The raise was executed in two tranches, with proceeds supporting near-term US deployments and commercial execution. Operating cash outflow rose modestly to A$851,000 for the quarter, reflecting increased investment in US commercial activities as HeraMED transitions from preparation to active market engagement. The company’s lean operating structure and dedicated US commercial team position it well to capitalise on upcoming deployment opportunities.

Scaling HeraCARE Platform and Australian Support

The HeraCARE platform continues to gain clinical traction, with over 4,450 registered mothers and more than 200,000 maternal vital measurements recorded to date. This growing dataset is critical for HeraMED’s data-as-an-asset strategy, which aims to enhance patient outcomes and embed HeraCARE as an enterprise solution. The company expects patient volumes to increase significantly as US deployments progress, expanding the clinical evidence base and recurring revenue potential.

Back home, HeraMED has secured acceptance into the Australian Government’s Industry Growth Program, offering advisory support on commercialisation strategy, funding pathways, and market testing. This complements the company’s international growth initiatives and underscores its commitment to scaling HeraCARE in multiple markets. This government support follows regulatory milestones such as the TGA Class IIb approval for HeraBEAT, reinforcing HeraMED’s positioning in digital maternity care, as discussed in the HeraMED regulatory milestone coverage.